Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: A case report

The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of non-small cell lung cancer (NSCLC). However, a number of skin manifestations have been found in patients receiving erlotinib therapy. Leukocytoclastic vasculitis is a rare side-eff...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2012-06, Vol.3 (6), p.1280-1282
Main Authors: SU, BO-AN, SHEN, WAN-LIN, CHANG, SHENG-TSUNG, FENG, LI-YIA, WU, CHIA-JUNG, FENG, YIN-HSUN
Format: Article
Language:English
Subjects:
erlotinib
leukocytoclastic vasculitis
lung cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of non-small cell lung cancer (NSCLC). However, a number of skin manifestations have been found in patients receiving erlotinib therapy. Leukocytoclastic vasculitis is a rare side-effect of erlotinib therapy. However, whether or not erlotinib treatment should be continued when disseminated ulceration of leukocytoclastic vasculitis is encountered remains to be determined. In this study, we report a patient with NSCLC who remains responsive to erlotinib treatment following successful rechallenge with a reduced dose of erlonitib after presenting with severe degree of leukoclastic vasculitis.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2012.647